Anavex Life Sciences

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Anavex Life Sciences Corp.
Public OTCQBAVXL
Industry Biopharmaceuticals
Headquarters New York, New York, USA
Key people
Christopher U. Missling, MS, PhD, MBA, President and CEO
Tom Skarpelos, Director
Michael Gold, MD, Scientific Advisory Board
Ottavio Arancio, MD, PhD, Scientific Advisory Board
Tangui Nicolas Maurice, Ph.D., Scientific Advisory Board
Paul Aisen, MD, Scientific Advisory Board – Clinical Expert
Jeffrey Cummings, MD, Scientific Advisory Board – Clinical Expert
Website anavex.com

Anavex Life Sciences Corp. is a pharmaceutical company that develops drug candidates.

ANAVEX 2-73 has been shown to provide protection from oxidative stress, which damages and destroys neurons and is believed to be a primary cause of Alzheimer's disease. Research in recent years indicates that oxidative stress is a precursor to amyloid-beta plaques and tau (see also Neuro-Fibrillary Tangles), and could be a novel and appropriate therapeutic target.[1]

See also[edit]

References[edit]

  1. ^ Nunomura A, Castellani RJ, Zhu X, Moreira PI, Perry G, Smith MA (July 2006). "Involvement of oxidative stress in Alzheimer disease". J. Neuropathol. Exp. Neurol. (Review) 65 (7): 631–41. doi:10.1097/01.jnen.0000228136.58062.bf. PMID 16825950. 

External links[edit]